Technology | Quality Assurance (QA) | July 10, 2019

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

New SciMoCa Monte Carlo patient QA enables fast and efficient quality assurance accuracy for Varian Halcyon in addition to all other major radiation therapy systems

IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019

July 10, 2019 — IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual American Association of Physicists in Medicine (AAPM) annual meeting, July 14-18 in San Antonio, Texas. The new release of SciMoCa provides what IBA calls the first and only worldwide commercial Monte Carlo Patient QA for the Varian Halcyon System.

Healthcare professionals can now verify all Halcyon treatment plans independently, accurately, and with an automated and efficient workflow. The fast Monte Carlo dose calculation enables highly accurate results even for the most challenging cases like non-coplanar stereotactic body radiation therapy (SBRT), and in particular for indications with tissue inhomogeneity like lung and head & neck treatments.

Monte Carlo is the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, the accuracy of Monte Carlo is now available for independent secondary dose calculation and patient QA (quality assurance) as well, allowing users to verify the most advanced treatment plans with an equally robust and fast QA solution. SciMoCa is used clinically for all standard linear accelerator (linac) types, for the Accuray CyberKnife and TomoTherapy/Radixact, and is now also compatible with Varian Halcyon.

The high-quality beam models for SciMoCa are created linac-specific for customers applying dedicated processes, expert tools and experience. This process allows an independent verification of the commissioning data and the TPS model, providing an additional level of peace of mind about the accuracy of the machine and TPS commissioning. This is particularly valuable for pre-commissioned treatment machines like Halcyon.

The SciMoCa software is manufactured by Radialogica LLC and globally distributed by IBA Dosimetry.

For more information: www.iba-dosimetry.com

Related Content

Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer